We are live on ! Find out more
ACM

Athyrium Capital Management Portfolio holdings

AUM $8.69M
1-Year Est. Return 34.58%
This Fund
S&P 500
This Quarter Est. Return
+0.16%
1 Year Est. Return
-34.58%
3 Year Est. Return
-25.1%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$169M
AUM Growth
–
Cap. Flow
+$1.15M
Cap. Flow %
0.68%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
APEN
Apollo Endosurgery, Inc.
APEN
+$1.15M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 0.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APEN
1
DELISTED
Apollo Endosurgery, Inc.
APEN
$1.41M 0.84%
+252,079
New +$1.15M

Similar funds

BGC
Birch Grove Capital New York $9.51M AUM 0.22% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
JDR
Jay D. Rosenbaum $6.69M AUM 4.68% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
KIM
Kaizen Investment Management Singapore $6.23M AUM
RJTCONH
Raymond James Trust Company of New Hampshire Portsmouth, New Hampshire $12.1M AUM 28.84% 1-Year Est. Return
HSC
Harbor Spring Capital New York $12.3M AUM
HVM
Harvest Volatility Management Norwalk, Connecticut $4.39M AUM 13.08% 1-Year Est. Return

Athyrium Capital Management's Q4 2017 Portfolio in Review

Q4 2017 is the first quarter with a 13F filing on record for Athyrium Capital Management, which disclosed 5 positions worth $169M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Apollo Endosurgery, Inc.: 252,079 shares worth $1.41M.

By sector, the portfolio is most concentrated in Healthcare at 0.84% of assets.

  • Athyrium Capital Management's largest Q4 2017 buy was Apollo Endosurgery, Inc.: 252,079 shares worth $1.41M.
  • Athyrium Capital Management's ten largest holdings make up 100% of its $169M portfolio in Q4 2017.
  • Athyrium Capital Management disclosed 5 positions in Q4 2017, its first 13F filing on record.

Based on Athyrium Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.